{"pmid":32321540,"title":"COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.","text":["COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.","On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei Province, and then rapidly spread worldwide. Italy was early and severely involved, with a critical spread of the infection and a very high number of victims. Person-to-person spread mainly occurs via respiratory droplets and contact. The median incubation period is 5 days. The spectrum of respiratory symptoms may range from mild to severe, strictly depending on the age of the patient and the underlying comorbidities.In children COVID-19 related disease is less frequent and less aggressive. In Italy 1% of positive cases are under 18 years of age, and no deaths have been recorded before 29 years of age. For patients affected by rheumatic disease, despite the concerns related to the imbalance of their immune response and the effect of immunosuppressive treatments, there are still few data to understand the real consequences of this infection. Major scientific societies have issued recommendations to help rheumatologists in caring their patients. Interestingly, some of the drugs mostly used by rheumatologists appear to be promising in critical COVID-19 infected patients, where the hyperinflammation and cytokine storm seem to drive to the multiorgan failure.Pediatric rheumatologists are expected to play a supporting role in this new front of COVID-19 pandemic, both as general pediatricians treating infected children, and as rheumatologists taking care of their rheumatic patients, as well as offering their experience in the possible alternative use of immunomodulatory drugs.","Pediatr Rheumatol Online J","Licciardi, Francesco","Giani, Teresa","Baldini, Letizia","Favalli, Ennio Giulio","Caporali, Roberto","Cimaz, Rolando","32321540"],"abstract":["On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei Province, and then rapidly spread worldwide. Italy was early and severely involved, with a critical spread of the infection and a very high number of victims. Person-to-person spread mainly occurs via respiratory droplets and contact. The median incubation period is 5 days. The spectrum of respiratory symptoms may range from mild to severe, strictly depending on the age of the patient and the underlying comorbidities.In children COVID-19 related disease is less frequent and less aggressive. In Italy 1% of positive cases are under 18 years of age, and no deaths have been recorded before 29 years of age. For patients affected by rheumatic disease, despite the concerns related to the imbalance of their immune response and the effect of immunosuppressive treatments, there are still few data to understand the real consequences of this infection. Major scientific societies have issued recommendations to help rheumatologists in caring their patients. Interestingly, some of the drugs mostly used by rheumatologists appear to be promising in critical COVID-19 infected patients, where the hyperinflammation and cytokine storm seem to drive to the multiorgan failure.Pediatric rheumatologists are expected to play a supporting role in this new front of COVID-19 pandemic, both as general pediatricians treating infected children, and as rheumatologists taking care of their rheumatic patients, as well as offering their experience in the possible alternative use of immunomodulatory drugs."],"journal":"Pediatr Rheumatol Online J","authors":["Licciardi, Francesco","Giani, Teresa","Baldini, Letizia","Favalli, Ennio Giulio","Caporali, Roberto","Cimaz, Rolando"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321540","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s12969-020-00422-z","keywords":["2019-ncov","covid-19","children","italy","respiratory syndrome","sars-cov-2"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"locations":["Wuhan","Hubei","Italy","Italy","multiorgan"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"_version_":1664895932673556480,"score":8.518259,"similar":[{"pmid":32207032,"title":"Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.","text":["Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.","Since December 2019, COVID-19 has occurred unexpectedly and emerged as a health problem worldwide. Despite the rapidly increasing number of cases in subsequent weeks, the clinical characteristics of pediatric cases are rarely described. A cross-sectional multicenter study was carried out in 10 hospitals across Hubei province. A total of 25 confirmed pediatric cases of COVID-19 were collected. The demographic data, epidemiological history, underlying diseases, clinical manifestations, laboratory and radiological data, treatments, and outcomes were analyzed. Of 25 hospitalized patients with COVID-19, the boy to girl ratio was 1.27:1. The median age was 3 years. COVID-19 cases in children aged <3 years, 3.6 years, and >/=6-years patients were 10 (40%), 6 (24%), and 9 (36%), respectively. The most common symptoms at onset of illness were fever (13 [52%]), and dry cough (11 [44%]). Chest CT images showed essential normal in 8 cases (33.3%), unilateral involvement of lungs in 5 cases (20.8%), and bilateral involvement in 11 cases (45.8%). Clinical diagnoses included upper respiratory tract infection (n=8), mild pneumonia (n=15), and critical cases (n=2). Two critical cases (8%) were given invasive mechanical ventilation, corticosteroids, and immunoglobulin. The symptoms in 24 (96%) of 25 patients were alleviated and one patient had been discharged. It was concluded that children were susceptible to COVID-19 like adults, while the clinical presentations and outcomes were more favorable in children. However, children less than 3 years old accounted for majority cases and critical cases lied in this age group, which demanded extra attentions during home caring and hospitalization treatment.","Curr Med Sci","Zheng, Fang","Liao, Chun","Fan, Qi-Hong","Chen, Hong-Bo","Zhao, Xue-Gong","Xie, Zhong-Guo","Li, Xi-Lin","Chen, Chun-Xi","Lu, Xiao-Xia","Liu, Zhi-Sheng","Lu, Wei","Chen, Chun-Bao","Jiao, Rong","Zhang, Ai-Ming","Wang, Jin-Tang","Ding, Xi-Wei","Zeng, Yao-Guang","Cheng, Li-Ping","Huang, Qing-Feng","Wu, Jiang","Luo, Xi-Chang","Wang, Zhu-Jun","Zhong, Yan-Yan","Bai, Yan","Wu, Xiao-Yan","Jin, Run-Ming","32207032"],"abstract":["Since December 2019, COVID-19 has occurred unexpectedly and emerged as a health problem worldwide. Despite the rapidly increasing number of cases in subsequent weeks, the clinical characteristics of pediatric cases are rarely described. A cross-sectional multicenter study was carried out in 10 hospitals across Hubei province. A total of 25 confirmed pediatric cases of COVID-19 were collected. The demographic data, epidemiological history, underlying diseases, clinical manifestations, laboratory and radiological data, treatments, and outcomes were analyzed. Of 25 hospitalized patients with COVID-19, the boy to girl ratio was 1.27:1. The median age was 3 years. COVID-19 cases in children aged <3 years, 3.6 years, and >/=6-years patients were 10 (40%), 6 (24%), and 9 (36%), respectively. The most common symptoms at onset of illness were fever (13 [52%]), and dry cough (11 [44%]). Chest CT images showed essential normal in 8 cases (33.3%), unilateral involvement of lungs in 5 cases (20.8%), and bilateral involvement in 11 cases (45.8%). Clinical diagnoses included upper respiratory tract infection (n=8), mild pneumonia (n=15), and critical cases (n=2). Two critical cases (8%) were given invasive mechanical ventilation, corticosteroids, and immunoglobulin. The symptoms in 24 (96%) of 25 patients were alleviated and one patient had been discharged. It was concluded that children were susceptible to COVID-19 like adults, while the clinical presentations and outcomes were more favorable in children. However, children less than 3 years old accounted for majority cases and critical cases lied in this age group, which demanded extra attentions during home caring and hospitalization treatment."],"journal":"Curr Med Sci","authors":["Zheng, Fang","Liao, Chun","Fan, Qi-Hong","Chen, Hong-Bo","Zhao, Xue-Gong","Xie, Zhong-Guo","Li, Xi-Lin","Chen, Chun-Xi","Lu, Xiao-Xia","Liu, Zhi-Sheng","Lu, Wei","Chen, Chun-Bao","Jiao, Rong","Zhang, Ai-Ming","Wang, Jin-Tang","Ding, Xi-Wei","Zeng, Yao-Guang","Cheng, Li-Ping","Huang, Qing-Feng","Wu, Jiang","Luo, Xi-Chang","Wang, Zhu-Jun","Zhong, Yan-Yan","Bai, Yan","Wu, Xiao-Yan","Jin, Run-Ming"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32207032","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s11596-020-2172-6","keywords":["COVID-19","SARS-CoV-2","children","coronavirus"],"source":"PubMed","locations":["China","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1663352133717590016,"score":262.31543},{"pmid":32166607,"pmcid":"PMC7090728","title":"A Review of Coronavirus Disease-2019 (COVID-19).","text":["A Review of Coronavirus Disease-2019 (COVID-19).","There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of coronavirus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The case fatality rate is estimated to range from 2 to 3%. Diagnosis is by demonstration of the virus in respiratory secretions by special molecular tests. Common laboratory findings include normal/ low white cell counts with elevated C-reactive protein (CRP). The computerized tomographic chest scan is usually abnormal even in those with no symptoms or mild disease. Treatment is essentially supportive; role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality. The global impact of this new epidemic is yet uncertain.","Indian J Pediatr","Singhal, Tanu","32166607"],"abstract":["There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of coronavirus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The case fatality rate is estimated to range from 2 to 3%. Diagnosis is by demonstration of the virus in respiratory secretions by special molecular tests. Common laboratory findings include normal/ low white cell counts with elevated C-reactive protein (CRP). The computerized tomographic chest scan is usually abnormal even in those with no symptoms or mild disease. Treatment is essentially supportive; role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality. The global impact of this new epidemic is yet uncertain."],"journal":"Indian J Pediatr","authors":["Singhal, Tanu"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32166607","week":"202011|Mar 09 - Mar 15","doi":"10.1007/s12098-020-03263-6","keywords":["2019-ncov","covid-19","pneumonia","review","sars-cov-2"],"source":"PubMed","topics":["Treatment","Mechanism","Prevention"],"weight":1,"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874751983616,"score":256.62378},{"pmid":32330332,"title":"SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic.","text":["SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic.","In December 2019, a cluster of patients with severe pneumonia caused by a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, China. The disease is now termed coronavirus disease 2019 (COVID-19). In the early reports, the patients were mainly middle-aged and elderly men, and children appeared to be less susceptible to this infection. With modern and efficient transportation, the disease quickly spread to almost all corners of the world and the mortality far exceeds those caused by severe acute respiratory syndrome coronavirus (SARS) or Middle East respiratory syndrome coronavirus (MERS). As the number of children with COVID-19 gradually increases, the disease has been documented in premature babies, infants, children and adolescents. Severe and fatal cases in children are relatively rare. The burden of disease in children has been relatively low, but the high proportions of asymptomatic or mildly symptomatic infections in children deserve careful attention. Clear understanding of the immune responses to the virus in children and the transmission potential of asymptomatic children are of paramount importance for the development of specific treatments and vaccine in order to effectively control the ongoing pandemic.","Pediatr Allergy Immunol","Lu, Xiaoxia","Xiang, Yun","Du, Hui","Wing-Kin Wong, Gary","32330332"],"abstract":["In December 2019, a cluster of patients with severe pneumonia caused by a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, China. The disease is now termed coronavirus disease 2019 (COVID-19). In the early reports, the patients were mainly middle-aged and elderly men, and children appeared to be less susceptible to this infection. With modern and efficient transportation, the disease quickly spread to almost all corners of the world and the mortality far exceeds those caused by severe acute respiratory syndrome coronavirus (SARS) or Middle East respiratory syndrome coronavirus (MERS). As the number of children with COVID-19 gradually increases, the disease has been documented in premature babies, infants, children and adolescents. Severe and fatal cases in children are relatively rare. The burden of disease in children has been relatively low, but the high proportions of asymptomatic or mildly symptomatic infections in children deserve careful attention. Clear understanding of the immune responses to the virus in children and the transmission potential of asymptomatic children are of paramount importance for the development of specific treatments and vaccine in order to effectively control the ongoing pandemic."],"journal":"Pediatr Allergy Immunol","authors":["Lu, Xiaoxia","Xiang, Yun","Du, Hui","Wing-Kin Wong, Gary"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330332","week":"202017|Apr 20 - Apr 26","doi":"10.1111/pai.13267","keywords":["sars-cov-2","children","coronavirus","immune response","pandemic"],"source":"PubMed","topics":["Treatment","Transmission","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664996914749243392,"score":235.9539},{"pmid":32304191,"title":"Novel coronavirus disease (COVID-19) in children","text":["Novel coronavirus disease (COVID-19) in children","Coronavirus disease (COVID-19) was firstly reported at the end of 2019. The disease rapidly spread all around the world in a few months and was declared a worldwide pandemic by WHO in March 2020. By April 9, there were 1,436,198 confirmed COVID-19 cases in the world, nearly with 6% mortality rate. This novel infectious disease causes respiratory tract illness that may generally occur as mild upper respiratory tract disease or pneumonia. In older patients and/or patients with underlying conditions, it may result in acute respiratory distress syndrome, multi organ failure and even death. According to the current literature, children account approximately for 1%-5% of diagnosed COVID-19 cases. Generally, COVID-19 seems to be a less severe disease for children than adults. Approximately 90% of pediatric patients are diagnosed as asymptomatic, mild, or moderate disease. However, up to 6.7% of cases may be severe. Severe illness is generally seen in patients smaller than 1 year of age and patients who have underlying disesases. The epidemiological and clinical patterns of COVID-19 and treatment approaches in pediatric patients still remain unclear although many pediatric reports are published. This review aims to summarize the current epidemics, clinical presentations, diagnosis, and treatment of COVID-19 in pediatric patients.","Turk J Med Sci","Tezer, Hasan","Bedir Demirdag, Tugba","32304191"],"abstract":["Coronavirus disease (COVID-19) was firstly reported at the end of 2019. The disease rapidly spread all around the world in a few months and was declared a worldwide pandemic by WHO in March 2020. By April 9, there were 1,436,198 confirmed COVID-19 cases in the world, nearly with 6% mortality rate. This novel infectious disease causes respiratory tract illness that may generally occur as mild upper respiratory tract disease or pneumonia. In older patients and/or patients with underlying conditions, it may result in acute respiratory distress syndrome, multi organ failure and even death. According to the current literature, children account approximately for 1%-5% of diagnosed COVID-19 cases. Generally, COVID-19 seems to be a less severe disease for children than adults. Approximately 90% of pediatric patients are diagnosed as asymptomatic, mild, or moderate disease. However, up to 6.7% of cases may be severe. Severe illness is generally seen in patients smaller than 1 year of age and patients who have underlying disesases. The epidemiological and clinical patterns of COVID-19 and treatment approaches in pediatric patients still remain unclear although many pediatric reports are published. This review aims to summarize the current epidemics, clinical presentations, diagnosis, and treatment of COVID-19 in pediatric patients."],"journal":"Turk J Med Sci","authors":["Tezer, Hasan","Bedir Demirdag, Tugba"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304191","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-174","keywords":["covid-19","novel corona virus","pediatrics"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1664632934562267136,"score":227.03064},{"pmid":32237160,"title":"Epidemiological analysis of COVID-19 and practical experience from China.","text":["Epidemiological analysis of COVID-19 and practical experience from China.","The rapid spread of the epidemic has aroused widespread concern in the international community. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and Middle East respiratory syndrome, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved.","J Med Virol","Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting","32237160"],"abstract":["The rapid spread of the epidemic has aroused widespread concern in the international community. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) originated from Wuhan's Huanan wholesale seafood market, with bats as the likely original hosts and pangolins as potential intermediate hosts. The current source of the disease is mainly patients infected with SARS-COV-2. Patients in the incubation period may also become sources of infection. The virus is mainly transmitted via respiratory droplets and contact, and the population is generally susceptible. The epidemic has progressed through the local outbreak stage and community transmission stage due to exposure at Wuhan's Huanan wholesale seafood market and is now in the stage of large-scale transmission due to the spread of the epidemic. The basic productive number (R0) at the beginning of the epidemic was 2.2, with an average incubation period of 5.2 days. The proportion of critically ill patients was 23.4%, the mortality rate was lower than those of SARS and Middle East respiratory syndrome, and 96.5% of deaths occurred in Hubei Province, where the outbreak occurred first. Among them, elderly men with underlying diseases had a higher mortality rate. Chinese medical staff have summarized a set of effective strategies and methods in the diagnosis and treatment of this disease that are worthy of reference for their international counterparts. With powerful government intervention and the efforts of Chinese medical staff, China's outbreak has gradually improved."],"journal":"J Med Virol","authors":["Ye, Qing","Wang, Bili","Mao, Jianhua","Fu, Junfen","Shang, Shiqiang","Shu, Qiang","Zhang, Ting"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237160","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25813","keywords":["covid-19","epidemic","mortality","treatment","virus pneumonia"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","Huanan","Wuhan","Huanan","Hubei","Chinese","Chinese","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638354184994817,"score":223.00314}]}